These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10534237)

  • 1. Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?
    Bever CT; Rosenberg GA
    Neurology; 1999 Oct; 53(7):1380-1. PubMed ID: 10534237
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
    Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
    Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate.
    Kieseier BC; Hartung HP
    Eur J Neurol; 2010 Mar; 17(3):344-5. PubMed ID: 20050905
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment.
    Liuzzi GM; Latronico T; Fasano A; Carlone G; Riccio P
    Mult Scler; 2004 Jun; 10(3):290-7. PubMed ID: 15222694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases biomarkers in multiple sclerosis.
    Rosenberg GA
    Lancet; 2005 Apr 9-15; 365(9467):1291-3. PubMed ID: 15823367
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
    Dhib-Jalbut S; Sumandeep S; Valenzuela R; Ito K; Patel P; Rametta M
    J Neuroimmunol; 2013 Jan; 254(1-2):131-40. PubMed ID: 22999187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of interferon beta at the time of initial diagnosis of multiple sclerosis.
    Pender MP
    J Clin Neurosci; 2001 Jul; 8(4):381-2. PubMed ID: 11437589
    [No Abstract]   [Full Text] [Related]  

  • 9. [New trends, clinical questions and long-term experiences. Therapy of multiple sclerosis with interferon beta-1b].
    Nervenarzt; 1998 Nov; 69(11 Suppl Therapie D):1-8. PubMed ID: 9845885
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon beta for treatment of multiple sclerosis.
    Wilson BA
    Medsurg Nurs; 1995 Apr; 4(2):151-3. PubMed ID: 7711824
    [No Abstract]   [Full Text] [Related]  

  • 11. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
    Hodgkinson SJ
    J Clin Neurosci; 2001 Jul; 8(4):378-9. PubMed ID: 11437587
    [No Abstract]   [Full Text] [Related]  

  • 12. [Betaferon and therapy of multiple sclerosis--present and future].
    Hohlfeld R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
    [No Abstract]   [Full Text] [Related]  

  • 13. Injecting rationale into interferon-beta therapy.
    Reder AT; Antel JP
    Neurology; 2000 Jun; 54(11):2034-5. PubMed ID: 10851357
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferons in multiple sclerosis.
    Kappos L
    Neurol Clin; 2005 Feb; 23(1):189-214, vii-viii. PubMed ID: 15661094
    [No Abstract]   [Full Text] [Related]  

  • 15. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 16. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon? The case against.
    Macdonell R
    J Clin Neurosci; 2001 Jul; 8(4):379-81. PubMed ID: 11437588
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
    Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
    Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High doses of interferon in the treatment of multiple sclerosis].
    Muñoz D
    Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
    Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
    Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pearls and pitfalls of interferon beta treatment for multiple sclerosis.
    Corona T; León C; Ruiz JL
    Neurologia; 1999 Nov; 14(9):467-8. PubMed ID: 10613023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.